55341-87-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
3-Aminothiophene-2-carboxylic acid is utilized as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its role in these industries is crucial for the production of a wide array of compounds that serve different therapeutic and agricultural purposes.
Used in Antitumor Research:
3-Aminothiophene-2-carboxylic acid is studied for its potential antitumor properties, indicating its possible use in the development of new cancer treatments. Its biological activity is of interest to researchers looking for novel compounds that can target and inhibit tumor growth.
Used in Antiviral Research:
Similarly, 3-Aminothiophene-2-carboxylic acid has been investigated for its potential antiviral properties, suggesting that it could be a candidate for the development of new antiviral medications. Its potential to combat viral infections makes it a valuable subject for further research and development in the field of virology.

InChI:InChI=1/C5H5NO2S/c6-3-1-2-9-4(3)5(7)8/h1-2H,6H2,(H,7,8)

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 65076-02-0 ethyl 2-ethoxycarbonyl-3-(thienylamino)prop-2-enoate 
• 50901-18-3 3-acetamidothiophene-2-carboxylic acid 
• 194088-56-7 3-((S)-2-Benzyloxycarbonylamino-3-tert-butoxy-propionylamino)-thiophene-2-carboxylic acid 
• 194088-58-9 3-[(S)-2-Benzyloxycarbonylamino-3-(trityl-carbamoyl)-propionylamino]-thiophene-2-carboxylic acid 
• 194088-59-0 3-[(S)-2-Benzyloxycarbonylamino-4-(trityl-carbamoyl)-butyrylamino]-thiophene-2-carboxylic acid 
• 17721-06-1 3-aminothiophene 
• 861965-63-1 thiophen‐3‐amine oxalate 
• 1254587-98-8 3-(3-benzylureido)thiophene-2-carboxylic acid 
• 319442-19-8 ethyl 4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine-2-carboxylate 
• 78756-28-2 2H-thieno[3,2-d][1,3]oxazine-2,4(1H)-dione 
• 147123-47-5 3-aminothiophene-2-carboxamide 
• 147123-52-2 3-phenylthieno<3,2-d>-1,2,3-triazin-4(3H)-one 
• 16234-10-9 3H-thieno[3,2-d]pyrimidin-4-one 
• 16269-66-2 4-chlorothieno[3,2-d]pyrimidine 

Relevant academic research and scientific papers

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

A 3 - amino - 2 - thiophene carboxylic acid isopropyl ester preparation method

The invention relates to a preparation method of 3-amido-2-isopropyl thiophenecarboxylate. The preparation method is characterized in that the 3-amido-2-thiophenic acid isopropyl ester is obtained through hydrolysis reaction, acylating chlorination reaction and esterification reaction by taking 3-amido-2-thiophenecarboxylate as a raw material. The preparation method disclosed by the invention solves the problem that a method for effectively preparing 3-amido-2-isopropyl thiophenecarboxylate is lack at present and has the characteristics of easily available raw material, low cost, high product yield and is easy and convenient to react and easy to amplify, and industrialized production is realized.

Thiophene/thiazole-benzene replacement on guanidine derivatives targeting α2-Adrenoceptors

Searching for improved antagonists of α2-adrenoceptors, a thorough theoretical study comparing the aromaticity of phenyl-, pyridinyl-, thiophenyl- and thiazolylguanidinium derivatives has been carried out [at M06-2X/6–311++G(p,d) computational level] confirming that thiophene and thiazole will be good ‘ring equivalents’ to benzene in these guanidinium systems. Based on these results, a small but chemically diverse library of guanidine derivatives (15 thiophenes and 2 thiazoles) were synthesised to explore the effect that the bioisosteric change has on affinity and activity at α2-adrenoceptors in comparison with our previously studied phenyl derivatives. All compounds were tested for their α2-adrenoceptor affinity and unsubstituted guanidinothiophenes displayed the strongest affinities in the same range as the phenyl analogues. In the case of cycloakyl systems, thiophenes with 6-membered rings showed the largest affinities, while for the thiazoles the 5-membered analogue presented the strongest affinity. From all the compounds tested for noradrenergic activity, only one compound exhibited agonistic activity, while two compounds showed very promising antagonism of α2-adrenoceptors.

Exploring the chemical space of ureidothiophene-2-carboxylic acids as inhibitors of the quorum sensing enzyme PqsD from Pseudomonas aeruginosa

Pseudomonas aeruginosa employs a quorum sensing (QS) communication system that makes use of small diffusible molecules. Among other effects, the QS system coordinates the formation of biofilm which decisively contributes to difficulties in the therapy of

Synthesis of Thieno[3,2-e][1,4]diazepin-2-ones: Application of an Uncatalysed Pictet-Spengler Reaction

A series of 5-substituted thieno[3,2-e][1,4]diazepin-2-ones was synthesized in four steps from methyl 3-aminothiophene-2-carboxylate. After the coupling of 3-aminothiophene with α-amino acids, the key final step that involves an uncatalysed Pictet-Spengler reaction allowed the cyclization of the seven-membered diazepinone ring. The reaction was first optimized and then exemplified in three different series (phenylalanine, alanine and proline) that led to 24 target diazepinones, which includes 19 optically pure diastereomers. A new synthetic approach that uses an uncatalysed Pictet-Spengler cyclization reaction has been developed to access [3,2-e]-type fused thienodiazepinones.

Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: Highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site

On the basis of X-ray co-crystal structures of matrix metalloproteinase-13 (MMP-13) in complex with its inhibitors, our structure-based drug design (SBDD) strategy was directed to achieving high affinity through optimal protein-ligand interaction with the unique S1″ hydrophobic specificity pocket. This report details the optimization of lead compound 44 to highly potent and selective MMP-13 inhibitors based on fused pyrimidine scaffolds represented by the thienopyrimidin-4-one 26c. Furthermore, we have examined the release of collagen fragments from bovine nasal cartilage in response to a combination of IL-1 and oncostatin M.

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.

Helical folding in heterogeneous foldamers without inter-residual backbone hydrogen-bonding

This communication describes a set of hybrid foldamers that do not feature inter-residual, but intra-residual backbone hydrogen-bonding, yet adopt a preferentially folded conformation displaying right-handed helical architecture. Conformational ordering is apparently due to the combined conformational restrictions imposed by the conformationally restricted individual amino acid residues with which the oligomers are made of.

ALPHA HELIX MIMETICS AND METHODS RELATING THERETO

Alpha-helix mimetic structures and compounds represented by the formula (I) wherein the general formula and the definition of each symbol are as defined in the specification, a chemical library relating thereto, and methods relating thereto, are disclosed. Applications of these compounds in the treatment of medical conditions, e.g., cancer diseases, fibrotic diseases, and pharmaceutical compositions comprising the mimetics are further disclosed.

New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as KATP channel openers: Modulation of the 4-position

The present work aimed at exploring a series of diversely 4-arylthiourea-substituted R/S-3,4-dihydro-2,2-dimethyl-6-halo-2H-1-benzopyrans structurally related to (±)-cromakalim. These new compounds were examined in vitro as putative potassium channel openers (PCOs) on rat pancreatic islets (inhibition of insulin release) as well as on rat aorta rings (relaxation of aorta ring) and their activity was compared to that of the reference KATP channel activators (±)-cromakalim, (±)-pinacidil, diazoxide and of previously reported cromakalim analogues. Structure-activity relationships indicated that the most pronounced inhibitory activity on the insulin secretory process was obtained with molecules bearing a strong meta- or para-electron-withdrawing group (CN or NO2) on the phenyl ring of the arylthiourea moiety at the 4-position of the benzopyran nucleus (compounds 12-23). Among those, R/S-6-chloro-4-(4-cyanophenylaminothiocarbonylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran (16) was found to be the most potent benzopyran-type inhibitor of insulin release ever described. Most of these original benzopyran derivatives show increased selectivity for pancreatic versus vascular tissue. Radioisotopic investigations indicated that these new compounds activated pancreatic KATP channels.